The bid is still a long way short of the $112 that Genentech is alleged to have valued itself at, according to a Roche filing with the US Securities and Exchange Commission.
Despite this, and the possibility that positive data from Avastin trials could send Genentech’s share price over $100, Franz Humer, chairman of the Roche Group, is confident the deal will go through.
Genentech has urged shareholders not to act until the Special Committee has taken a formal position, which will happen “promptly”.
Eight months, three bids, no deal
It is now almost eight months since Roche made its initial $43.7bn bid for Genentech, with developments since then revealing an increasingly fraught relationship.
To provide a unique overview of these developments in-PharmaTechnologist presents an interactive flipbook of the news since day one, with the headlines providing links to the complete articles.